Nucleoside Switch Pilot for Virologically Controlled HIV Subjects With Decreasing CD4 Cells Who Have Received TDF-based ARV Therapy

Next Previous
Trial Profile

Nucleoside Switch Pilot for Virologically Controlled HIV Subjects With Decreasing CD4 Cells Who Have Received TDF-based ARV Therapy

Completed
Phase of Trial: Phase IV

Latest Information Update: 02 May 2017

At a glance

  • Drugs Lamivudine/abacavir (Primary)
  • Indications HIV-1 infections
  • Focus Therapeutic Use
  • Acronyms EPZSwitch

    • Most Recent Events

    • 27 Apr 2017 Status changed from recruiting to completed.
    • 08 Jun 2012 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top